Table S1 in Supplementary Materials shows all the target and immuno-therapies approved for advanced/metastatic NSCLC, with the related approval date by EMA. The first anti-Epithelia growth factor receptor (EGFR) approved as first line was gefitinib, in 2009 by EMA, followed by Crizotinib, an Anaplastic lymphoma kinase (ALK) inhibitor, in 2012. The gene discussed is ALK; the disease is non-small cell lung carcinoma.